doc. MUDr. Jana Štefaničková, PhD.
Vedecko/umelecko-pedagogická charakteristika:
Najvýznamnejšie výstupy tvorivej činnosti: VTC1, VTC2, VTC3, VTC4, VTC5
1. | Stefanickova J, Cunha-Vaz J, Ulbig M, Pearce I, Fernández-Vega Sanz A, et al.; POLARIS study investigators. A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS). Acta Ophthalmolologica. 2018 | Q1 | IF 3,153 |
2. | Krasnik V, Stefanickova J, Popov I, Valaskova J, Saxena S, Kruzliak P. Prevalence of Age-Related Macular Degeneration in Slovakia and Associated Risk Factors: A Mobile Clinic-Based Cross-Sectional Epidemiological Survey. Seminars in Ophthalmology. 2018 | Q4 | IF 1,401 |
3. | Ankita A, Saxena S, Nim DK, Stefanickova J, Ziak P, Stefanicka P, Kruzliak P. Retinal photoreceptor apoptosis is associated with impaired serum ionized calcium homeostasis in diabetic retinopathy: An in-vivo analysis. Journal of Diabetes and its Complications. 2019 | Q3 | IF 2,781 |
4. | Ankita A, Stefanickova J, Saxena S, Nim DK, Ahmad K, Mahdi AA, Kaur A, Bhasker SK, Valaskova J, Kruzliak P. Hyperglycemia potentiates the effect of ionic calcium in photoreceptor ellipsoid zone disruption in diabetic retinopathy. International Ophthalmology. 2019 | Q2 | IF 1,314 |
5. | Garweg JG, Štefanickova J, Hoyng C, Niesen T, Schmelter T, Leal S, Sivaprasad S; VIOLET Investigators. Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial. Advances in therapy. 2022 | Q1 | IF 3,847 |